Antisense peptide nucleic acids (PNAs) are emerging as a promising tool in the fight against bacterial infections, particularly those caused by multidrug-resistant strains. These synthetic ...

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

(NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs ...

The Nucleic Acids Institute is dedicated to understanding the chemical and biological basis for nucleic acid function, and to developing new and powerful nucleic acids based therapeutic and ...

In this study, we tested if locked nucleic acid (LNA) miR-181a-5p antisense oligonucleotides (ASO) could be used as a therapeutic to limit articular cartilage degeneration. Methods We used a variety ...

Furin is identified as the key enzyme responsible for cleaving the apelin precursor. Inhibiting this cleavage could serve as ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Although in excess of 30 nucleic acid-based drugs (i.e., gene therapy/vaccines, antisense, and ribozymes) are currently being evaluated, the majority remain in the early stages of clinical ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

Beijing Key Laboratory for Bioengineering and Sensing Technology, Daxing Research Institute, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing ...

A company that is working on advancing non-viral delivery technologies for nucleic acid therapeutics, such as mRNA, small interfering ribonucleic acid (siRNA), and antisense oligonucleotides (ASOs ...